NCT05384821 2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2 Recruiting
Clinical Trials
74 trialsNCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06709495 2026-02-19
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07391215 2026-02-05
5G-PEARL
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT06630260 2026-01-21
5G-RUBY
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT07346157 2026-01-16
PNOC044
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT05588453 2026-01-12
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT03212742 2025-12-04
OLA-TMZ-RTE-01
Centre Francois Baclesse
Phase 1/2 Active not recruiting
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT07141771 2025-08-26
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Not yet recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT02715609 2025-04-10
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1/2 Completed
NCT03213002 2025-04-09
CAPTEM
Northwell Health
Phase 1/2 Recruiting
NCT06721689 2025-03-26
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT04881032 2025-02-13
NANO-GBM
Centre Jean Perrin
Phase 1/2 Active not recruiting
NCT03914742 2025-01-14
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT01985087 2024-10-31
A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
University of Louisville
Phase 1/2 Active not recruiting
NCT06258018 2024-08-30
ONC-2022-001
Istituto Clinico Humanitas
Phase 1/2 Not yet recruiting
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT05664464 2024-05-10
GLUGLIO
University of Zurich
Phase 1/2 Recruiting
NCT03466450 2024-03-28
GEINOGLAS
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT05663125 2022-12-23
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Beijing Tiantan Hospital
Phase 1/2 Unknown
NCT03119064 2022-12-13
329
Brown University
Phase 1/2 Terminated
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT02770378 2021-10-05
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
Phase 1/2 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01120639 2021-08-06
Tx-Treatment
Stanford University
Phase 1/2 Completed
NCT02046187 2021-06-16
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT00961844 2021-02-26
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Oslo University Hospital
Phase 1/2 Terminated
NCT00050986 2020-09-22
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04547621 2020-09-14
HSCK-010
Huashan Hospital
Phase 1/2 Unknown
NCT01590082 2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00576680 2020-07-09
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT04388033 2020-06-09
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT00275067 2020-02-25
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Northwestern University
Phase 1/2 Unknown